February 2007
Worldwide Biotech;Feb2007, Vol. 19 Issue 2, p5
Trade Publication
The article reports that a pharmaceutical company has utilized Digilab's sample preparation and fractionation technologies to expose standard and novel diabetes substrates in a Fourier Mass Spectroscopy experimental paradigm. David Giddings, president and CEO of Digilab Inc., said that the company was pleased to know that its peptidomics sample have proven beneficial to drug discovery and development.


Related Articles

  • Accelerating Drug Development for Diabetes. Hussain, Lubna // Drug Discovery & Development;Jul/Aug2013, Vol. 16 Issue 4, p12 

    The article focuses on the research and development of drugs for the treatment of diabetes. It is inferred that research institutions are focusing on the optimization of immunosuppressants, generation of beta cells from stem cells and the advancement of post-islet transplantation response. A...

  • Record number of diabetes meds in development.  // Pharmacy Today;Jul2009, Vol. 15 Issue 7, p3 

    The article cites a report by the Pharmaceutical Research and Manufacturers of America (PhRMA) showing that American pharmaceutical research and biotechnology companies are testing 183 new diabetes medications. PhRMA president Billy Tauzin claims that the medications are contributing to the...

  • Global partnerships for health.  // WHO Drug Information;1999, Vol. 13 Issue 1, p1 

    Discusses ways by which access to affordable, innovative and essential drugs can be improved through research in the pharmaceutical industry. Drug strategy revision; Action program on essential drugs; Norms, standards and regulations for implementation by regulatory authorities.

  • Feds Challenge Payments to PBMs, Docs. Wechsler, Jill // Pharmaceutical Executive;Jun2003, Vol. 23 Issue 6, p30 

    Lists pharmaceutical industry practices that could draw fraud charges by the U.S. Office of the Inspector General. Need for manufacturers to include all data in reporting best prices to Medicaid, Medicare and other government agencies; Implications of making excessive payments and gifts to...

  • Realism in drug discovery?could Cassandra be right? Horrobin, David F. // Nature Biotechnology;Dec2001, Vol. 19 Issue 12, p1099 

    Comments on failures of pharmaceutical firms in the field of drug discovery. New products required by drug firms to sustain their growth; Factors contributing to failures in pharmaceutical research.

  • Pharmaceutical Research. Laubach, Gerald D. // BioScience;Nov1967, Vol. 17 Issue 11, p778 

    The article discusses several reports published in the issue including one on the chemistry of natural products and another on fertility-regulating drugs.

  • Drug companies and the new millennium. Goldblatt, Dan // Business News New Jersey;12/07/98, Vol. 11 Issue 44, p8 

    Cites a study which looked into the cost of pharmaceutical research and development. Doctor Steve Arlington's presentation of the findings before a group of senior executives from drug companies; Predicted slowdown in the rate of sales increases in the United States; Profusion of new drug...

  • Further Reading.  // PharmaWatch: Monthly Review;Feb2008, Vol. 7 Issue 2, p35 

    A list of reports related to pharmaceutical industry is presented.

  • Europe Hopes to Stop Pharma Research Exodus to the Us.  // Chemical Market Reporter;5/20/2002, Vol. 261 Issue 20, p6 

    Reports on the formation of G10 on Medicines, a united front to prevent European drug companies from transferring a growing proportion of their activities to the U.S. Factors that lead to the shift of pharmaceutical companies' research and development activities from Europe to the U.S.; Impact...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics